logo-loader
viewOpen Orphan PLC

Open Orphan names chair of newly established Advisory Board to guide on searching for solutions to coronavirus outbreak

Professor John Oxford is a professor at Queen Mary's University London and one of the world's leading experts on global diseases such as influenza, including bird flu, SARS, MERS and coronavirus

Coronavirus
The group said Professor Oxford will chair the Advisory Board alongside Professor Brendan Buckley, a director of Open Orphan

Open Orphan PLC (LON:ORPH), the rapidly growing specialist CRO pharmaceutical services company, has announced the appointment of Professor John Oxford as chair of a newly established Advisory Board which will initially focus on guiding the company on the provision of solutions to the current coronavirus outbreak.

Professor Oxford is a professor at Queen Mary's University London and one of the world's leading experts on global diseases such as influenza, including bird flu, SARS, MERS and coronavirus.

READ: Open Orphan gets £5mln from City fundraiser that will be used to accelerate growth post-merger

The AIM-listed firm - which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, and has Europe's only 24 bedroom quarantine clinic with onsite virology lab in Queen Mary's Hospital London - said the Advisory Board has been established to help the company support product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness of the coronavirus in 2020.

The group said Professor Oxford will chair the Advisory Board alongside Professor Brendan Buckley, a director of Open Orphan.

At the end of last year, Open Orphan launched an all-share merger with fellow AIM-listed pharma group hVIVO.

Quick facts: Open Orphan PLC

Price: 14.25 GBX

AIM:ORPH
Market: AIM
Market Cap: £78.24 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan's Cathal Friel on its £12mln raise to accelerate coronavirus...

Open Orphan PLC's (LON:ORPH) Cathal Friel speaks to Proactive London's Andrew Scott after announcing they've raised approximately £12mln to ramp up its coronavirus (COVID-19) antiviral testing. Friel says the fundraise has brought many new leading blue-chip institutional shareholders to their...

3 days, 14 hours ago

2 min read